Skip to main content may receive compensation from affiliate partners for some links on the site. Read our full Disclosure here.

26.9% of New York State Medicare-Aged Patients Who Received Fauci’s 5-Day Remdesivir Protocol Died, Says Dr. Bryan Ardis (WATCH)


Dr. Bryan Ardis spoke about the dangers of the toxic antiviral remdesivir, the first drug to receive FDA approval to treat hospitalized COVID-19 patients.

In a recent public hearing, Ardis said he’s warned since May 2020 that “remdesivir will result in at least 30% deaths of everyone who receives that drug in a hospital for 5 to 10 days.”

Ardis explained how he used CMS data pulled by Attorney Thomas Renz and calculated the death rate of New York state Medicare-aged patients placed on the 5-day remdesivir protocol.

Watch Ardis explain his findings below:

26.9% of them died,” Ardis stated.

“Remdesivir as of October 2021 was found by the Cardiovascular Toxicology Journal that it actually causes death of heart cells and is cardiotoxic. And can lead to cardiac arrest.”

As stated by Cardiovascular Toxicology:

Some patients with COVID-19 infection on remdesivir may develop sinus bradycardia, hypotension, T-wave abnormalities, AF, and a prolonged QT interval. Also, few cases of cardiac arrest and complete heat block following remdesivir infusion have been reported. It seems remdesivir have some cardiotoxic and proarrhythmic effects that are especially more pronounced in patients with previous cardiovascular diseases. Continuous cardiac rhythm monitoring is recommended in patients undergoing remdesivir treatment. It is especially advisable in individuals with any known cardiac diseases or electrolyte disturbances. Furthermore, we should be more cautious about additive cardiovascular adverse effects when other drug classes are used in addition to remdesivir treatment. It is due to the fact that their combination may increase the risk of potential fatal ventricular arrhythmias or cardiac arrest. The current safety profile of remdesivir is still not completely known. Further prospective clinical trials can assist us to know more about its safety profile and potential adverse cardiovascular effects.

“December 16th your FDA, I’m sorry your NIH with that Anthony Fauci there, decided to update now all guidelines for treatment drugs allowed and approved for COVID-19 in Americans. Guess what’s the only listed drug FDA-approved for hospitalized Americans? Remdesivir,” Ardis stated.

As Ardis noted, the WHO recommends against the use of remdesivir:

WHO has issued a conditional recommendation against the use of remdesivir in hospitalized patients, regardless of disease severity, as there is currently no evidence that remdesivir improves survival and other outcomes in these patients.

“You know what’s more disgusting? January 21st of this year, the FDA extended an emergency use authorization and said there’s now only one authorized medication that can be pumped into the veins of all newborns in this country to 18-year-old pediatric aged-ranged children, starting with 7-pound newborns. Guess what the only authorized drug to treat COVID-19 children is now, in hospitals and outside? Remdesivir,” Ardis explained.

Read the updated guidelines HERE.

FDA Expands Emergency Use Authorization of Remdesivir to Pediatric Patients Under 12 Years of Age


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Thanks for sharing!